Health & Biotech
Stories by Tim Boreham
Health & Biotech
Health Kick Podcast: Novel gene targeting therapies, protein disruptors and why ANP’s recent trial success have investors buzzing
Health & Biotech
Dr Boreham’s Crucible: This is the only ASX-listed biotech in the photodynamic therapy game
Health & Biotech
Health Kick Podcast: Learning from the Swine flu pandemic, the market potential of exosome therapeutics and jumping ASX life-sciences hurdles
Health & Biotech
Dr Boreham’s Crucible: Polynovo moves onto hernia treatments after conquering burns market
Health & Biotech
Dr Boreham’s Crucible: Avita in for a busy 2020 with big expansion ambitions
Health & Biotech
Health Kick Podcast: Commercialising orphan drugs, the need for better regulation and the ASX’s lifestyle play problem
Health & Biotech
Dr Boreham’s Crucible: MedAdvisor could cure what ails it by shelving its expansion plans
Health & Biotech
Health Kick Podcast: The science behind 2019’s hottest IPO and the company’s plans for 2020
Health & Biotech
Dr Boreham’s Crucible: Memphasys now feeling the investor love for its IVF tech
Health & Biotech
Health Kick Podcast: Investing in repurposed drugs, combating intracranial pressure and why Invex caught NASA’s eye
Health & Biotech